Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications

Overview

Journal AJR Am J Roentgenol

Specialties Oncology
Radiology

Date 2018 Jun 28

PMID 29949419

Citations 16

Authors

Thomas A Hope

Ali Afshar-Oromieh

Matthias Eiber

Louise Emmett

Wolfgang P Fendler

Courtney Lawhn-Heath

Steven P Rowe

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer.

Conclusion: PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

Citing Articles

Brain imaging and machine learning reveal uncoupled functional network for contextual threat memory in long sepsis.

Strohl J, Carrion J, Huerta P Sci Rep. 2024; 14(1):27747.

PMID: 39533062 PMC: 11557587. DOI: 10.1038/s41598-024-79259-5.

From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer.

Hameed M, Gul M, Chaudhry A, Muzaffar H, Sheikh M, Chee W Cancers (Basel). 2024; 16(17).

PMID: 39272896 PMC: 11394180. DOI: 10.3390/cancers16173039.

Meta-analysis of F-PSMA-1007 PET/CT, F-FDG PET/CT, and Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer.

Yu W, Zhao M, Deng Y, Liu S, Du G, Yan B Cancer Imaging. 2023; 23(1):77.

PMID: 37605288 PMC: 10440897. DOI: 10.1186/s40644-023-00599-y.

PSMA PET imaging in the diagnosis and management of prostate cancer.

Houshmand S, Lawhn-Heath C, Behr S Abdom Radiol (NY). 2023; 48(12):3610-3623.

PMID: 37493837 PMC: 10682054. DOI: 10.1007/s00261-023-04002-z.

PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma.

Yuile A, Lee A, Moon E, Hudson A, Kastelan M, Miller S Biomedicines. 2023; 11(4).

PMID: 37189766 PMC: 10135493. DOI: 10.3390/biomedicines11041148.

References

Beheshti M, Kunit T, Haim S, Zakavi R, Schiller C, Stephens A . BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study). Mol Imaging Biol. 2014; 17(3):424-33. DOI: 10.1007/s11307-014-0800-x. View

Hofman M, Hicks R, Maurer T, Eiber M . Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics. 2018; 38(1):200-217. DOI: 10.1148/rg.2018170108. View

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

Fragomeni R, Amir T, Sheikhbahaei S, Harvey S, Javadi M, Solnes L . Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018; 59(6):871-877. DOI: 10.2967/jnumed.117.203570. View

Roehl K, Han M, Ramos C, Antenor J, Catalona W . Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172(3):910-4. DOI: 10.1097/01.ju.0000134888.22332.bb. View

Kozikowski A, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T . Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001; 44(3):298-301. DOI: 10.1021/jm000406m. View

Giesel F, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W . F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016; 44(4):678-688. PMC: 5323462. DOI: 10.1007/s00259-016-3573-4. View

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B . Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2):125-135. PMC: 5895095. DOI: 10.1056/NEJMoa1607427. View

Eiber M, Maurer T, Souvatzoglou M, Beer A, Ruffani A, Haller B . Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015; 56(5):668-74. DOI: 10.2967/jnumed.115.154153. View

10.

Hope T, Truillet C, Ehman E, Afshar-Oromieh A, Aggarwal R, Ryan C . 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2016; 58(1):81-84. PMC: 5209643. DOI: 10.2967/jnumed.116.181800. View

11.

Cookson M, Aus G, Burnett A, Canby-Hagino E, DAmico A, Dmochowski R . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in.... J Urol. 2007; 177(2):540-5. DOI: 10.1016/j.juro.2006.10.097. View

12.

Pandey M, Byrne J, Jiang H, Packard A, DeGrado T . Cyclotron production of (68)Ga via the (68)Zn(p,n)(68)Ga reaction in aqueous solution. Am J Nucl Med Mol Imaging. 2014; 4(4):303-10. PMC: 4074496. View

13.

Banerjee S, Foss C, Castanares M, Mease R, Byun Y, Fox J . Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008; 51(15):4504-17. PMC: 3336105. DOI: 10.1021/jm800111u. View

14.

Hope T, Aggarwal R, Chee B, Tao D, Greene K, Cooperberg M . Impact of Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017; 58(12):1956-1961. DOI: 10.2967/jnumed.117.192476. View

15.

Haider M, Chung P, Sweet J, Toi A, Jhaveri K, Menard C . Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 70(2):425-30. DOI: 10.1016/j.ijrobp.2007.06.029. View

16.

Maurer T, Gschwend J, Rauscher I, Souvatzoglou M, Haller B, Weirich G . Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2015; 195(5):1436-1443. DOI: 10.1016/j.juro.2015.12.025. View

17.

Rowe S, Pienta K, Pomper M, Gorin M . Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0. J Nucl Med. 2017; 59(3):479-485. PMC: 6910634. DOI: 10.2967/jnumed.117.195255. View

18.

Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q . Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015; 56(8):1185-90. DOI: 10.2967/jnumed.115.160382. View

19.

Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley W, Sokol G . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-74. DOI: 10.1016/j.ijrobp.2006.04.029. View

20.

Cho S, Gage K, Mease R, Senthamizhchelvan S, Holt D, Jeffrey-Kwanisai A . Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012; 53(12):1883-91. PMC: 3742115. DOI: 10.2967/jnumed.112.104661. View